Hydroxychloroquine Market, By Disease Type (Coronavirus Disease (COVID-19), Malaria, Q Fever, Rheumatoid Arthritis, Lupus Erythematosus, Porphyria Cutanea Tarda (PCT), and Other Disease Types), By Distribution Channel (Specialty Drug Store, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2029

Report Code: PMI431920 | Publish Date: March 2024 | No. of Pages: 178

Global Hydroxychloroquine Market Companies

  • Mylan N.V.
  • Wallace Pharmaceuticals Ltd.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Zydus Cadila Ltd.
  • Ipca Laboratories Ltd.
  • Cipla Limited
  • Lupin Limited

No news

  • In February 2022, Accord Healthcare Inc. introduced additional strengths of hydroxychloroquine sulfate tablets in the United States. The generic version of Plaquenil, hydroxychloroquine, is commonly used to treat malaria, lupus, and rheumatoid arthritis. The creation and commercialization of these unique capabilities demonstrates Accord's commitment to addressing unmet patient needs for accurate dosing of critical medications in the United States. The newly released product complements the previous version of Hydroxychloroquine 200 mg tablets.
  • In March 2020, Novartis International AG began supplying 30 million doses of hydroxychloroquine tablets to the U.S. Department of Health and Human Services (HHS) for supervised clinical trials to evaluate the efficacy of hydroxychloroquine in patients with coronavirus disease (Covid 19).